Stock VRTS VIRTUS INVESTMENT PARTNERS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Virtus Investment Partners, Inc.

Equities

VRTS

US92828Q1094

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
227.6 USD -1.37% Intraday chart for Virtus Investment Partners, Inc. +0.99% -5.87%
Apr. 26 Virtus Investment Partners Q1 Adjusted Earnings, Revenue Increase MT
Apr. 26 Earnings Flash (VRTS) VIRTUS INVESTMENT PARTNERS Posts Q1 Revenue $222M MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Virtus: Q1 Earnings Snapshot
AQ
Virtus Investment Partners Announces Financial Results for First Quarter 2024
BU
Virtus Investment Partners to Announce First Quarter 2024 Results on Friday, April 26
BU
Virtus Investment Partners Reports Preliminary March 31, 2024 Assets Under Management
BU
Virtus Investment Partners Reports Preliminary February 29, 2024 Assets Under Management
BU
Virtus Artificial Intelligence & Technology Opportunities Fund Announces Distributions and Discloses Sources of Distribution - Section 19(a) Notice
BU
Virtus Investment Partners Declares Quarterly Cash Dividend on Common Stock
BU
Virtus Investment Partners Reports Preliminary January 31, 2024 Assets Under Management
BU
Virtus Investment Partners : Fourth Quarter 2023 Transcript
PU
Virtus: Q4 Earnings Snapshot
AQ
Virtus Investment Partners Announces Financial Results for Fourth Quarter 2023
BU
Virtus Investment Partners Reports Preliminary December 31, 2023 Assets Under Management
BU
Virtus Investment Partners to Transfer Listing of Common Stock to New York Stock Exchange
BU
Virtus Investment Partners Reports Preliminary November 30, 2023 Assets Under Management
BU
Virtus Investment Partners Declares Quarterly Cash Dividend on Common Stock
BU
Virtus Introduces the Virtus Newfleet Short Duration Core Plus Bond ETF
BU
Virtus Investment Partners Names Andra Purkalitis Executive Vice President and Chief Legal Officer
BU
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
PR
Virtus Investment Partners Reports Preliminary October 31, 2023 Assets Under Management
BU
Virtus: Q3 Earnings Snapshot
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VRTS Stock
  4. News Virtus Investment Partners, Inc.
  5. Press Releases